Zhitong Finance App News, Jianfeng Group (600668.SH) issued an announcement. Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for injectable tedizolamide phosphate approved and issued by the State Drug Administration. Tedizolamide phosphate is suitable for the treatment of acute bacterial skin and skin soft tissue infections (ABSSSI) caused by sensitive isolates of the following gram-positive bacteria: Staphylococcus aureus (including isolates of methicillin-resistant Staphylococcus aureus [MRSA] and methicillin-sensitive Staphylococcus aureus [MSSA]), Streptococcus pyogenes, streptococcus angina (including streptococcus angina, intermediate streptococcus, and streptococcus constellation) and enterococcus faecalis.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Jianfeng Group (600668.SH) issued an announcement. Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for injectable tedizolamide phosphate approved and issued by the State Drug Administration. Tedizolamide phosphate is suitable for the treatment of acute bacterial skin and skin soft tissue infections (ABSSSI) caused by sensitive isolates of the following gram-positive bacteria: Staphylococcus aureus (including isolates of methicillin-resistant Staphylococcus aureus [MRSA] and methicillin-sensitive Staphylococcus aureus [MSSA]), Streptococcus pyogenes, streptococcus angina (including streptococcus angina, intermediate streptococcus, and streptococcus constellation) and enterococcus faecalis.